LifePro Asset Management Sells 384 Shares of Zoetis Inc. (NYSE:ZTS)

LifePro Asset Management trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 14.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,189 shares of the company’s stock after selling 384 shares during the quarter. LifePro Asset Management’s holdings in Zoetis were worth $408,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. AAFMAA Wealth Management & Trust LLC boosted its stake in shares of Zoetis by 0.3% during the second quarter. AAFMAA Wealth Management & Trust LLC now owns 19,390 shares of the company’s stock valued at $3,614,000 after purchasing an additional 50 shares in the last quarter. Chicago Partners Investment Group LLC lifted its stake in Zoetis by 3.1% in the second quarter. Chicago Partners Investment Group LLC now owns 1,650 shares of the company’s stock valued at $331,000 after buying an additional 50 shares during the period. 1ST Source Bank increased its holdings in shares of Zoetis by 0.7% during the second quarter. 1ST Source Bank now owns 7,003 shares of the company’s stock valued at $1,305,000 after acquiring an additional 50 shares in the last quarter. Highland Private Wealth Management increased its holdings in shares of Zoetis by 3.3% during the second quarter. Highland Private Wealth Management now owns 1,622 shares of the company’s stock valued at $303,000 after acquiring an additional 52 shares in the last quarter. Finally, SFE Investment Counsel increased its holdings in shares of Zoetis by 0.8% during the second quarter. SFE Investment Counsel now owns 6,851 shares of the company’s stock valued at $1,277,000 after acquiring an additional 55 shares in the last quarter. 89.53% of the stock is currently owned by hedge funds and other institutional investors.

In other Zoetis news, EVP Roxanne Lagano sold 22,450 shares of the stock in a transaction that occurred on Thursday, July 22nd. The stock was sold at an average price of $199.18, for a total value of $4,471,591.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kristin C. Peck sold 14,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 25th. The shares were sold at an average price of $203.55, for a total value of $2,951,475.00. Following the completion of the transaction, the chief executive officer now owns 43,424 shares of the company’s stock, valued at approximately $8,838,955.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,003 shares of company stock valued at $9,711,854. Company insiders own 0.17% of the company’s stock.

ZTS traded up $0.77 on Wednesday, hitting $204.32. 18,070 shares of the company were exchanged, compared to its average volume of 1,790,607. The firm has a fifty day simple moving average of $203.07 and a two-hundred day simple moving average of $181.17. The company has a debt-to-equity ratio of 1.51, a quick ratio of 2.51 and a current ratio of 3.37. Zoetis Inc. has a 12 month low of $141.41 and a 12 month high of $210.10. The stock has a market capitalization of $96.84 billion, a PE ratio of 50.78, a price-to-earnings-growth ratio of 3.31 and a beta of 0.64.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 5th. The company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.11. Zoetis had a return on equity of 53.87% and a net margin of 25.76%. During the same quarter last year, the business posted $0.89 EPS. On average, equities analysts expect that Zoetis Inc. will post 4.53 earnings per share for the current year.

Several research analysts have weighed in on the company. Barclays boosted their price objective on Zoetis from $208.00 to $235.00 and gave the stock an “overweight” rating in a research report on Friday, August 6th. Cantor Fitzgerald upped their target price on Zoetis from $210.00 to $238.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 13th. Argus upped their target price on Zoetis from $195.00 to $225.00 and gave the stock a “buy” rating in a research note on Wednesday, August 25th. Raymond James lowered Zoetis from an “outperform” rating to a “market perform” rating in a research note on Friday, July 16th. Finally, Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $186.00 price objective on the stock in a research report on Tuesday, June 1st. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $199.08.

Zoetis Company Profile

Zoetis, Inc discovers, develops, and manufactures a portfolio of animal health medicines and vaccines. The firm operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices, and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.

Recommended Story: Growth Stocks

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.